Q-omics provides the consensus-scored CCDC191 profile across patient tissues and cancer cell-line models. CCDC191 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, CCDC191 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, CCDC191 RNA expression shows 20,071 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BLCA, KICH, and THYM as cancer lineages where CCDC191 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC191 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC191 survival associations across molecular data types. CCDC191 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC191 RNA expression–survival associations across cancer types. High CCDC191 expression shows unfavorable associations in LGG, but favorable associations in BLCA, BRCA, READ, SKCM and KIRP. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for CCDC191 RNA expression.
This table summarizes CCDC191 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CCDC191. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC191 shows lower tumor expression in KICH, THCA, LUSC and LUAD and higher tumor expression in LIHC and CHOL. The KICH box plot shows higher CCDC191 RNA expression in normal versus tumor tissue (log2 FC = −2.050, t-test p < 0.001).
This table shows molecular features associated with CCDC191 in patient tissues and cancer cell lines. In patient samples, CCDC191 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC191 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and UPPER_AERODIGESTIVE_TRACT.
